Antiproliferative activity of cisplatin detected by CFSE in p53-proficient and p53-deficient cells

Immunological Investigations

Volumn 36, Issue 5-6, 2007, Pages 847-859

  Ubezio, Paolo ^a   Lupi, Monica ^a   Matera, Giada ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cell division; Cell proliferation; CFSE; Cisplatin; Complexity; Drug effects; Flow cytometry

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CISPLATIN; DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; COLON CARCINOMA; DRUG DETERMINATION; DRUG EFFECT; GENE FREQUENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WILD TYPE;

CISPLATIN; FLUORESCEINS; FLUOROMETRY; GENES, P53; HUMANS; SUCCINIMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37649024139     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130701674836     Document Type: Article

References (18)

1. Aneja, R., Ghaleb, A.M., Zhou, J., Yang, V.W., Joshi, H.C. (2007). p53 and p21 Determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 67:3862-3870.
2. 1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23:973-980.
3. Bargonetti, J., Manfredi, J.J. (2002). Multiple roles of the tumor suppressor p53. Curr. Op. Oncol. 14:86-91.
4. Blandino, G., Levine, A.J., Oren, M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485.
5. Brattain, M.G., Fine, W.D., Khaled, F.M., Thompson, J., Brattain, D.E. (1981). Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res. 41:1751-1756.
6. 1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 96:1002-1007.
7. 2 arrest after DNA damage. Science 282:1497-1501.
8. el-Deiry, W.S. (1998). Regulation of p53 downstream genes. Semin. Cancer Biol. 8:345-357.
9. Hollstein, M., Sidransky, D., Vogelstein, B., Harris C.C. (1991). p53 mutations in human cancers. Science 253:49-53.
10. 2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 96:2147-2152.
11. Lupi, M., Matera, G., Natoli, C., Colombo, V., Ubezio, P. (2007). The contribution of p53 in the dynamics of cell cycle response to DNA damage interpreted by a mathematical model. Cell Cycle 6:943-950.
12. Lyons, A.B., Parish, C.R. (1994). Determination of lymphocyte division by flow cytometry. J. Immunol. Meth. 171:131-137.
13. Matera, G., Lupi, M., Ubezio, P. (2004). Heterogeneous cell response to topotecan in a CFSE-based proliferation test. Cytometry 62A:118-128.
14. Vikhanskaya, F., Colella, G., Valenti, M., Parodi, S., D'Incalci, M., Broggini, M. (1999). Cooperation between p53 and hMLH1 in a human coloncarcinoma cell line in response to DNA damage. Clin. Cancer Res. 5:937-941.
15. Vogelstein, B., Lane, D., Levine, A.J. (2000). Surfing the p53 network. Nature 408:307-310.
16. Vousden, K.H. (2006). Outcomes of p53 activation - spoilt for choice. J. Cell Sci. 119:5015-5020.
17. Vousden, K.H., Lu, X. (2002). Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604.
18. Weston, S.A., Parish, C.R. (1990). New fluorescent dyes for lymphocyte migration studies. Analysis by flow cytometry and fluorescence microscopy. J. Immunol. Meth. 133:87-97.